ADVM vs. IPHA, IPSC, KOD, INMB, ABOS, ZURA, CMPX, OPT, CGEN, and ELEV
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Innate Pharma (IPHA), Century Therapeutics (IPSC), Kodiak Sciences (KOD), INmune Bio (INMB), Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Compass Therapeutics (CMPX), Opthea (OPT), Compugen (CGEN), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
Innate Pharma (NASDAQ:IPHA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.
Adverum Biotechnologies' return on equity of 0.00% beat Innate Pharma's return on equity.
Innate Pharma presently has a consensus price target of $9.75, suggesting a potential upside of 273.58%. Adverum Biotechnologies has a consensus price target of $29.00, suggesting a potential upside of 216.25%. Given Adverum Biotechnologies' higher probable upside, equities research analysts plainly believe Innate Pharma is more favorable than Adverum Biotechnologies.
In the previous week, Adverum Biotechnologies had 9 more articles in the media than Innate Pharma. MarketBeat recorded 13 mentions for Adverum Biotechnologies and 4 mentions for Innate Pharma. Adverum Biotechnologies' average media sentiment score of 0.47 beat Innate Pharma's score of 0.13 indicating that Innate Pharma is being referred to more favorably in the media.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Adverum Biotechnologies received 325 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 60.91% of users gave Adverum Biotechnologies an outperform vote while only 54.29% of users gave Innate Pharma an outperform vote.
Innate Pharma has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Innate Pharma has higher revenue and earnings than Adverum Biotechnologies.
Summary
Innate Pharma and Adverum Biotechnologies tied by winning 7 of the 14 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
